Redmile Group LLC Has $178.30 Million Position in Atara Biotherapeutics Inc (NASDAQ:ATRA)
Redmile Group LLC increased its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 1.6% in the first quarter, HoldingsChannel.com reports. The fund owned 4,485,417 shares of the biotechnology company’s stock after purchasing an additional 70,800 shares during the quarter. Atara Biotherapeutics accounts for approximately 5.2% of Redmile Group LLC’s portfolio, making the stock its 4th largest position. Redmile Group LLC owned 0.10% of Atara Biotherapeutics worth $178,295,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in ATRA. JPMorgan Chase & Co. lifted its stake in Atara Biotherapeutics by 53.8% in the first quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock worth $76,237,000 after acquiring an additional 671,216 shares during the period. Norges Bank purchased a new stake in Atara Biotherapeutics in the fourth quarter worth about $20,648,000. Federated Investors Inc. PA lifted its stake in Atara Biotherapeutics by 47.6% in the first quarter. Federated Investors Inc. PA now owns 903,307 shares of the biotechnology company’s stock worth $35,906,000 after acquiring an additional 291,207 shares during the period. Dimensional Fund Advisors LP lifted its stake in Atara Biotherapeutics by 107.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock worth $16,500,000 after acquiring an additional 245,832 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Atara Biotherapeutics in the fourth quarter worth about $6,673,000.
A number of brokerages have commented on ATRA. Stifel Nicolaus began coverage on shares of Atara Biotherapeutics in a report on Wednesday, May 22nd. They issued a “buy” rating and a $41.00 target price for the company. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 4th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $23.00 to $24.00 in a report on Monday, June 3rd. ValuEngine upgraded shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Finally, Mizuho reiterated a “buy” rating and issued a $62.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $40.40.
ATRA opened at $21.85 on Monday. Atara Biotherapeutics Inc has a 52-week low of $21.31 and a 52-week high of $47.22. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96. The stock has a market cap of $1.01 billion, a PE ratio of -4.15 and a beta of 2.36.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.48) by $0.04. On average, analysts anticipate that Atara Biotherapeutics Inc will post -5.54 earnings per share for the current fiscal year.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
See Also: Market Perform
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.